Veltassa (patiromer) approved in Japan to treat adult patients with hyperkalemia
CSL/Vifor announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd. (Zeria), marketing authorization approval for Veltassa for the treatment of adult patients with hyperkalemia, a condition characterized by high levels of potassium in the blood
Veltassa has now received marketing authorizations in 41 countries worldwide.
The approval is based on the marketing authorization application filing by Zeria, which was supported by positive clinical data from the Japanese clinical development program of ZG-801 (Veltassa) conducted in patients with hyperkalemia in Japan. In 2018., CSL Vifor granted Zeria the exclusive right to develop and market Veltassa in Japan. Zeria expects to begin to market Veltass following National Health Insurance price listing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.